高分子量角蛋白，CKl9及TP0联合检测在鉴别甲状腺乳头状癌与乳头状增生中的意义  

Differential diagnostic usefulness of 34 β El2, CK19 and TP0 in papillary thyroid car-einoma and papillary thyroid hyperplasia

作　　者：江鹤灵[1] 胡名娟[1] 李国伟[1] 

机构地区：[1]广州市花都区人民医院病理科,510800

出　　处：《国际医药卫生导报》2012年第6期846-849,共4页International Medicine and Health Guidance News

摘　　要：目的探讨高分子量角蛋白（34βE12），CKl9及TP0联合检测在甲状腺乳头状癌及甲状腺良性乳头状增生诊断及鉴别诊断中的应用价值和意义。方法应用免疫组化方法检测38例甲状腺乳头状癌及15例结节性甲状腺肿伴乳头状增生、15例滤泡性腺瘤伴乳头状增生病变中高分子量角蛋白（34βE12）、CKl9及TP0表达情况。结果34βE12、CKl9及TP0在甲状腺乳头状癌和甲状腺良性乳头状增生（结节性甲状腺肿伴乳头状增生及滤泡性腺瘤伴乳头状增生）中的阳性率分别为89．5％与33％（P〈0．01），84．2％与16．7％（P〈0．01），10．5％与96．7％（P〈0．011。结论34βE12，CKl9及TP0联合检测有助于甲状腺乳头状癌与甲状腺良性乳头状增生的诊断与答别诊断。Abstract To study the application value and significance of 34E12, cytokeratin 19 （CK l 9）and thyroper oxidase（TP0） in the differential diagnosis between papillary thyroid carcinomas and benign thyroid papillary hyperplasia. Methods The expression of 34 β E 12, CK19 and TP0 protein in 38 cases of papillary thyroid carcinomas, 15 cases of thyroid nodular goiter with papillary hyperplasia and 15 cases of adenomas with papillary hyperplasia were detected by immunohistochemistry method. Results The positive rats of 34β E 12, CK19 and TP0 in papillary thyroid carcinomas and hyperplasia diseaseof thyroid were 89.5% and 3.3% （P〈 0.01）; 84.2% and 16.7% （P〈 0.01）; 10.5% and 96.7% （P〈 0.01）. Conclusion 34β El2, CK19 and TP0 expressions are useful in differential diagnosis for papillary thyroid carcinoma and benign papillary thyroid hyperplasia.

关 键 词：甲状腺乳头状癌 高分子量角蛋白(34 β E12) CK19 TP0 免疫组化 

分 类 号：R736.1[医药卫生—肿瘤]